Study of GlaxoSmithKline Platelet Drug, Promacta Halted Due to Clots

May 13, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- U.S. regulators said on Wednesday a study among liver-disease patients taking GlaxoSmithKline's (GSK.L)(GSK.N) Promacta treatment for low blood platelets was halted due to blood-clot safety issues.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research

GlaxoSmithKline